About I Wish I Knew What I Know Now: Conversations With AGG on FDA Issues
Our podcast series hosts strategic conversations at the center of life sciences, law, and policy. During each episode, AGG’s former government attorneys bring firsthand knowledge and updates from their respective agencies — such as the HHS and DOJ — and examine how the latest regulatory developments and enforcement trends impact life sciences organizations. These insider insights, paired with the practical experience of AGG’s Life Sciences (https://www.agg.com/services/life-sciences/) team, offer the life sciences industry a map of the road ahead in today’s regulatory environment.
Patient Assistance Programs and the False Claims Act: Enforcement Trends and Compliance Risks for Life Sciences Companies
In this episode, AGG Life Sciences co-chair Alan Minsk is joined by AGG Healthcare and Life Sciences partner David Blank, former Senior Counsel at the HHS Office of Inspector General ("OIG"), for an in-depth discussion on Patient Assistance Programs ("PAPs"), the False Claims Act ("FCA"), and evolving enforcement priorities impacting life sciences companies. Drawing on his experience at OIG and advising companies today, David unpacks how DOJ and OIG are approaching market access, patient sup...
14 Nov 2025
How Medicare Regulations Could Affect Access to Gender-Affirming Care: Implications for Life Sciences Companies
In this episode, AGG Life Sciences co-chair Alan Minsk and Healthcare partner Andrew Tsui examine how the Centers for Medicare & Medicaid Services ("CMS") may apply the Medicare Conditions of Participation ("COPs") to emerging areas of healthcare, including gender-affirming care — and what those developments could mean for pharmaceutical companies and drug manufacturers. They discuss how updates to COPs can impact operational requirements for healthcare providers and influence compliance...
7 Oct 2025
DOJ’s Shifting Enforcement: CPB Disbanding, Counterfeit Drug Focus, and Gender-Affirming Care Investigations
In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Gabe Scannapieco, Litigation and Healthcare partner and Life Sciences co-chair, unpack recent shifts at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations. They discuss the disbanding of DOJ’s Consumer Protection Branch ("CPB") and what the loss of centralized oversight could mean for coordinated investigations i...
15 Aug 2025
HHS Policy Changes, Supreme Court Rulings, and the DOJ-HHS False Claims Act Working Group
In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Brian Stimson, co-chair of the Healthcare practice and former acting general counsel and principal deputy general counsel of the U.S. Department of Health and Human Services ("HHS"), discuss three recent developments affecting life sciences companies. Alan and Brian review the HHS policy-making process, including the formal requirements for changing policies that have un...
23 Mar 2023
Tell Me Lies, Tell Me Sweet Little Lies: FDA Is Not My Only Potential Headache When It Comes to Product Promotion
In this episode, Alan G. Minsk, AGG Food & Drug team leader, and Anuj Desai, AGG Intellectual Property partner and head of Trademarks, discuss recent developments that remind our audience in the food and drug space that FDA is not the only regulatory agency that’s keeping an eye on the marketplace. Alan and Anuj look at how NAD, a BBB program that supports advertising self-regulation, recently addressed a challenge in the prescription drug space. They also talk about how FTC investigative...
27 Sept 2021
Business Divorces in the Food and Supplements Space
In this episode, Michael E. Burke, partner and co-chair of the Pharmaceutical & Biotechnology industry team is joined by Robert Durkin, an attorney in our Dietary Supplements team, as they discuss issues around business divorces or disputes between companies in the food and supplements space. They will discuss, among other things, post-divorce product regulatory status and related business challenges, as well as strategies that can be employed at the beginning of the business relationship...
29 Jun 2021
Fee Waivers for Small Businesses: Who Qualifies for the Small Business User Fee Waiver for Drugs and Biologics and How to Apply from an FDA and Corporate Perspective
In this episode, AGG’s Food & Drug team leader, Alan G. Minsk, and Genevieve M. Razick, an attorney in our Healthcare and Food & Drug practices, along with Leah D. Braukman, an attorney in our Corporate & Finance practice, discuss the specifics of the small business user fee waiver, who qualifies, and how to apply from an FDA and corporate perspective.
1 Mar 2021
Data Privacy Issues Life Sciences Companies May Encounter
In this episode, AGG’s Food & Drug team leader, Alan G. Minsk, and co-chair of AGG’s Data Privacy practice, Kevin L. Coy, discuss U.S. and international privacy and data security law issues life sciences companies may encounter such as privacy policies, the patchwork of federal and state privacy and data security laws in the U.S., international data protection laws, such as GDPR, and related international data transfer issues.
1 Feb 2021
FDA Regulation of Rx Drug and Medical Device Advertising and Promotion: 2020 Year in Review
In this episode, AGG’s Food & Drug team leader, Alan G. Minsk, and team member, Genevieve M. Razick, give an overview of FDA’s Office of Prescription Drug Promotion’s (OPDP) enforcement of unlawful advertising in 2020.
1 Jan 2021
FDA Regulated Natural Products: Leveraging IP and Regulatory Requirements to Maximize Possible Return on Investment
In this episode, partner Kevin M. Bell and of counsel Bob Durkin discuss some of the more interesting issues and challenges they have encountered when working with clients to ensure they maximized opportunities to monetize the greatest value from their natural products and how a well thought out and executed regulatory strategy can help.
1 Dec 2020
Pandemic Marketing 101: Do’s and Don’ts to Market Your Brands, Products, and Services Safely
In this episode, partner Anuj Desai and of counsel Carolina M. Wirth discuss the Federal Trade Commission (FTC) and Food and Drug Administration's (FDA) roles of protecting consumers at the height of a public health crisis and the types of advertising and legal compliance issues that have surfaced in the past several months as well as provide a recap of agency actions.
1 Nov 2020
Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
In this episode, Alan G. Minsk, partner and leader of the Food & Drug practice team, is joined by Brian A. Teras, partner of the Corporate & Securities practice team. They provide an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process.
1 Oct 2020
Quality Agreements for FDA-Regulated Products: Looking Under the Hood
In our inaugural episode, Alan G. Minsk, partner and leader of the Food & Drug practice team, is joined by Michael E. Burke, co-chair of the Pharmaceuticals & Biologics industry team. They discuss issues around quality agreements for FDA regulated products as well as topics related to manufacturing, FDA timelines and compliance with relevant national authorities.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Podcast Authority Score: 12 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
23
Social presence
0
YouTube
0
Engagement
0
Contact I Wish I Knew What I Know Now: Conversations With AGG on FDA Issues
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of I Wish I Knew What I Know Now: Conversations With AGG on FDA Issues?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
